CN108358968B - 一种替诺福韦的制备方法 - Google Patents
一种替诺福韦的制备方法 Download PDFInfo
- Publication number
- CN108358968B CN108358968B CN201810288514.XA CN201810288514A CN108358968B CN 108358968 B CN108358968 B CN 108358968B CN 201810288514 A CN201810288514 A CN 201810288514A CN 108358968 B CN108358968 B CN 108358968B
- Authority
- CN
- China
- Prior art keywords
- solvent
- tenofovir
- reduced pressure
- reaction
- adenine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 title claims abstract description 102
- 229960004556 tenofovir Drugs 0.000 title claims abstract description 96
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 239000003054 catalyst Substances 0.000 claims abstract description 97
- MJZYTEBKXLVLMY-UHFFFAOYSA-N 1-(6-aminopurin-9-yl)propan-2-ol Chemical compound N1=CN=C2N(CC(O)C)C=NC2=C1N MJZYTEBKXLVLMY-UHFFFAOYSA-N 0.000 claims abstract description 80
- 238000006460 hydrolysis reaction Methods 0.000 claims abstract description 48
- RUOJZAUFBMNUDX-GSVOUGTGSA-N (4r)-4-methyl-1,3-dioxolan-2-one Chemical compound C[C@@H]1COC(=O)O1 RUOJZAUFBMNUDX-GSVOUGTGSA-N 0.000 claims abstract description 38
- UOEFFQWLRUBDME-UHFFFAOYSA-N diethoxyphosphorylmethyl 4-methylbenzenesulfonate Chemical compound CCOP(=O)(OCC)COS(=O)(=O)C1=CC=C(C)C=C1 UOEFFQWLRUBDME-UHFFFAOYSA-N 0.000 claims abstract description 33
- 229960000643 adenine Drugs 0.000 claims abstract description 32
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229930024421 Adenine Natural products 0.000 claims abstract description 31
- 239000002904 solvent Substances 0.000 claims description 121
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 119
- 238000006243 chemical reaction Methods 0.000 claims description 109
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 105
- 238000004321 preservation Methods 0.000 claims description 95
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 90
- 238000001816 cooling Methods 0.000 claims description 87
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 85
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 78
- 238000001914 filtration Methods 0.000 claims description 78
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 74
- 238000010438 heat treatment Methods 0.000 claims description 64
- 239000003960 organic solvent Substances 0.000 claims description 60
- 239000012043 crude product Substances 0.000 claims description 58
- 229960001355 tenofovir disoproxil Drugs 0.000 claims description 54
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 claims description 54
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical group CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 48
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 45
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 claims description 43
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 37
- 238000001035 drying Methods 0.000 claims description 36
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical group [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 32
- 239000003513 alkali Substances 0.000 claims description 31
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 30
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 29
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 28
- 239000000047 product Substances 0.000 claims description 21
- 230000035484 reaction time Effects 0.000 claims description 18
- 239000000126 substance Substances 0.000 claims description 15
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 claims description 14
- 238000006555 catalytic reaction Methods 0.000 claims description 14
- 238000004821 distillation Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 125000003944 tolyl group Chemical group 0.000 claims description 13
- 238000001704 evaporation Methods 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 abstract description 4
- 238000006482 condensation reaction Methods 0.000 abstract description 2
- 238000006266 etherification reaction Methods 0.000 abstract description 2
- 238000007670 refining Methods 0.000 abstract description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000002253 acid Substances 0.000 description 17
- 239000012535 impurity Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 8
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 8
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 8
- IVSZLXZYQVIEFR-UHFFFAOYSA-N m-xylene Chemical group CC1=CC=CC(C)=C1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 8
- 239000002994 raw material Substances 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- KAHAOCBTSPIUJJ-RXMQYKEDSA-N NC1=C2N=CN=C2N(C=N1)C[C@@H](C)O Chemical group NC1=C2N=CN=C2N(C=N1)C[C@@H](C)O KAHAOCBTSPIUJJ-RXMQYKEDSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 4
- 229940078552 o-xylene Drugs 0.000 description 4
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 description 2
- KTVKQTNGWVJHFL-UHFFFAOYSA-N 2-ethylchromen-4-one Chemical compound C1=CC=C2OC(CC)=CC(=O)C2=C1 KTVKQTNGWVJHFL-UHFFFAOYSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000005580 one pot reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- GJQYTEXMDZPNSH-UHFFFAOYSA-N 1-(6-aminopurin-7-yl)propan-2-ol Chemical compound C1=NC(N)=C2N(CC(O)C)C=NC2=N1 GJQYTEXMDZPNSH-UHFFFAOYSA-N 0.000 description 1
- XSJFZURMEFSSEG-XCGJVMPOSA-N 1-[(6R)-6-aminopurin-6-yl]propan-2-ol Chemical compound OC(C[C@@]1(C2=NC=NC2=NC=N1)N)C XSJFZURMEFSSEG-XCGJVMPOSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- QRBPRPXDUFXPGR-UHFFFAOYSA-N 2-methoxypropyl dihydrogen phosphate Chemical compound COC(C)COP(O)(O)=O QRBPRPXDUFXPGR-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229940123527 Nucleotide reverse transcriptase inhibitor Drugs 0.000 description 1
- 125000000848 adenin-9-yl group Chemical group [H]N([H])C1=C2N=C([H])N(*)C2=NC([H])=N1 0.000 description 1
- 230000000798 anti-retroviral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810288514.XA CN108358968B (zh) | 2018-04-03 | 2018-04-03 | 一种替诺福韦的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810288514.XA CN108358968B (zh) | 2018-04-03 | 2018-04-03 | 一种替诺福韦的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108358968A CN108358968A (zh) | 2018-08-03 |
CN108358968B true CN108358968B (zh) | 2020-09-15 |
Family
ID=63001725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810288514.XA Active CN108358968B (zh) | 2018-04-03 | 2018-04-03 | 一种替诺福韦的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108358968B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109053804B (zh) * | 2018-08-31 | 2021-03-30 | 乐平市赛复乐医药化工有限公司 | 一种替诺福韦的合成方法 |
CN111039857A (zh) * | 2019-12-25 | 2020-04-21 | 苏州雅尼生物科技有限公司 | 一种高纯度吡非尼酮的制备方法 |
CN111943982B (zh) * | 2020-08-14 | 2023-10-10 | 山东罗欣药业集团股份有限公司 | 一种抗病毒药物的合成工艺 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69722004T2 (de) * | 1996-07-26 | 2004-04-01 | Gilead Sciences, Inc., Foster City | Nukleotidanaloga |
SG106657A1 (en) * | 1997-07-25 | 2004-10-29 | Gilead Sciences Inc | Nycleotide analog composition and sythesis method |
CN101279987A (zh) * | 2007-04-05 | 2008-10-08 | 江西麒麟化工有限公司 | 泰诺福韦生产工艺 |
CN102295660A (zh) * | 2011-07-04 | 2011-12-28 | 常州大学 | 泰诺福韦的合成工艺 |
CN104725423A (zh) * | 2013-12-18 | 2015-06-24 | 山东新时代药业有限公司 | 一种富马酸替诺福韦二吡呋酯的合成方法 |
CN105985381B (zh) * | 2014-12-30 | 2018-10-30 | 安徽贝克联合制药有限公司 | 一种替诺福韦的制备方法 |
CN105859781A (zh) * | 2016-05-03 | 2016-08-17 | 荆门市帅邦化学科技有限公司 | 一种泰诺福韦的产业化生产工艺 |
-
2018
- 2018-04-03 CN CN201810288514.XA patent/CN108358968B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN108358968A (zh) | 2018-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108358968B (zh) | 一种替诺福韦的制备方法 | |
US8846896B2 (en) | Methods of preparing substituted nucleotide analogs | |
EP2262756B1 (en) | Process for preparing alkyl 2-alkoxymethylene-4,4-difluoro-3-oxobutyrates | |
EP2072503B1 (en) | Process for the preparation of bosentan | |
KR20170073649A (ko) | 치환된 뉴클레오시드 유사체의 제조 방법 | |
US7064205B2 (en) | Process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid | |
EP2734506B1 (en) | Process for the synthesis of cyclic alkylene ureas | |
CN104418807A (zh) | 一种2-乙氧基-1-[[2`-(羟基脒基)-联苯基]-4-基]甲基-1h-苯并咪唑-7-羧酸及其酯衍生物的制备方法 | |
JP2022163113A (ja) | プリン誘導体を調製するための方法 | |
US20190084921A1 (en) | Method of preparation of 4-isopropylamino-1-butanol | |
CN109608468B (zh) | 一种枸橼酸托法替布杂质及其合成方法和用途 | |
WO2010032261A1 (en) | Process for preparation of bosentan | |
CN108822174A (zh) | 新型核苷修饰物2’-eoe-鸟嘌呤核苷及其制备方法 | |
KR101471047B1 (ko) | 고순도 보센탄의 개선된 제조방법 | |
EP3543225B1 (en) | Method for preparing lisinopril intermediate | |
CN114072386A (zh) | 制备用于合成艾曲波帕或其盐的关键中间体的改进方法 | |
EP1210347A1 (en) | Carbocyclic nucleosides and process for obtaining such | |
AU2009284898B2 (en) | Method for producing a-hydroxyester compound | |
US7223871B2 (en) | Process for preparing substituted imidazole derivatives and intermediates used in the process | |
EP2170837A2 (en) | Process for preparing 2-(3-{6-[2-(2,4-dichlorophenyl)-ethylamino]-2-methoxypyrimidin-4-yl)-phenyl)-2-methylpropionic acid | |
CN117105877A (zh) | 一种1,4,8,11-四氮杂环十四烷的制备方法 | |
CN112028835A (zh) | 一种盐酸利匹韦林杂质及其合成方法 | |
CN117510337A (zh) | 一种贝前列素及其盐的中间体的制备方法 | |
JP2888333B2 (ja) | 抗ウイルス剤 | |
EP2298782A1 (en) | Method for producing pyrazole glycoside derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 2666 Chuangye Road, Mingshui Development Zone, Zhangqiu District, Jinan City, Shandong Province Applicant after: Kexing biopharmaceutical Co., Ltd. Address before: 250200 2666 Chuang Road, Ming Shui development area, Zhangqiu District, Ji'nan, Shandong. Applicant before: Shandong Kexing Biological Product Co., Ltd. |
|
CB02 | Change of applicant information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Jun Inventor after: Guo Chao Inventor after: Ren Shiping Inventor after: Cui Ning Inventor after: Zhang Yun Inventor before: Cui Ning Inventor before: Hao Zhihai Inventor before: Zhang Yun Inventor before: Wang Jun Inventor before: Guo Chao Inventor before: Ren Shiping Inventor before: Wang Cuicui Inventor before: Chou Duxian |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |